Midatech Pharma Plc (LON:MTPH, NASDAQMTP) boss tells us how the company has secured a US$15mln, four-year senior loan facility that will be used to bankroll the clinical development of two promising cancer drug candidates. The funding has come via MidCap Financial, a middle market finance house, and Midtech has drawn down an initial US$7mln of the facility. CEO Jim Phillips tells Proactive what this will mean for Midatech during 2018 while giving us detail on new clinical trials on three different products.
New loan for Midatech promises greater profitability
Quick facts: Midatech Pharma PLC
Price: 21.5 GBX
Market Cap: £5.05 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Midatech Pharma PLC named herein, including the promotion by the Company of Midatech Pharma PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE